Puma Biotechnology, Inc.: Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
Puma Biotech's Nerlynx Included In NCCN Guidelines For Breast Cancer - Puma Biotechnology (NASDAQ:PBYI) - Benzinga